Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
HEPA | US
-0.07
-8.30%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.75
0.74
0.83
0.70
Hepion Pharmaceuticals Inc. a biopharmaceutical company focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH) as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis liver inflammation liver tumor burden and titers of HBV HCV HDV and HIV-1 and has demonstrated antiviral activities for hepatitis B C and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals Inc. and changed its name to Hepion Pharmaceuticals Inc. in July 2019. Hepion Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Edison New Jersey.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
142.8%1 month
112.7%3 months
98.2%6 months
97.0%-
-
2.33
0.04
0.03
-0.10
-
-
-31.51M
4.35M
4.35M
-
-
-
-
-189.52
1.15
0.43
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.34
Range1M
0.34
Range3M
0.48
Rel. volume
1.34
Price X volume
71.45K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CNS PHARMACEUTICALS INC | CNSP | Biotechnology | 0.146 | 4.69M | 19.67% | n/a | -2.87% |
Azitra Inc | AZTR | Biotechnology | 0.61 | 4.65M | 0.00% | 0.01 | 41.86% |
ADTX | ADTX | Biotechnology | 1.09 | 4.60M | 3.81% | n/a | 122.46% |
Pasithea Therapeutics Corp. Common Stock | KTTA | Biotechnology | 4.39 | 4.59M | 1.62% | n/a | 0.00% |
AquaBounty Technologies Inc | AQB | Biotechnology | 1.1 | 4.25M | -8.33% | n/a | 10.41% |
Titan Pharmaceuticals Inc | TTNP | Biotechnology | 4.58 | 4.19M | -4.38% | n/a | 0.00% |
NuCana plc | NCNA | Biotechnology | 1.86 | 4.18M | -1.06% | n/a | 0.00% |
Fresh America Corp | FRES | Biotechnology | 1.66 | 4.07M | -15.74% | n/a | 0.22% |
Lipella Pharmaceuticals Inc. Common Stock | LIPO | Biotechnology | 0.4896 | 3.97M | -0.99% | n/a | 5.50% |
Windtree Therapeutics Inc | WINT | Biotechnology | 1.07 | 3.94M | 17.16% | n/a | 36.99% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.10 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 2.33 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 98.16 | 72.80 | Riskier |
Debt to Equity | 0.04 | -1.23 | Expensive |
Debt to Assets | 0.03 | 0.25 | Cheaper |
Market Cap | 4.35M | 3.66B | Emerging |